NUP88: A Potential Drug Target for Cancer (G4927)

Target Name: NUP88

NCBI ID: G4927

NUP88

NUP88: A Potential Drug Target for Cancer

NUP88 (MGC8530) is a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. Its primary function is to regulate the cell division process, which is crucial for the growth and development of tissues. NUP88 has also been shown to play a role in the regulation of cellular processes that are important for the development and progression of cancer.

Recent studies have identified NUP88 as a potential drug target for the treatment of various diseases, including cancer. The reason for its potential as a drug target is its ability to interact with multiple signaling pathways, as well as its expressed levels in various tissues, which makes it an attractive target for drug developers.

One of the key mechanisms by which NUP88 has been shown to contribute to the development of cancer is its role in the regulation of the cell cycle. NUP88 is a key component of the microtubule, which is the protein structure that organizes the mitotic spindle that pulls the chromosomes during cell division. In cancer cells, the regulation of the cell cycle is often disrupted, leading to uncontrolled cell growth and the formation of tumors.

NUP88 has been shown to play a role in the regulation of the microtubule dynamics, which is crucial for the maintenance of the integrity of the mitotic spindle. This is important for the regulation of chromosomal stability and the proper formation of the cell plate during cell division.

Another mechanism by which NUP88 has been shown to contribute to the development of cancer is its role in the regulation of the actin cytoskeleton. The actin cytoskeleton is the protein structure that provides structural support to the cell, and it is involved in various cellular processes, including the regulation of cell division and the movement of cells. In cancer cells, the actin cytoskeleton is often disrupted, leading to the loss of cell stability and the formation of tumors.

NUP88 has been shown to play a role in the regulation of the actin cytoskeleton by interacting with the protein cofilin. Cofilin is a protein that is involved in the regulation of actin dynamics and is expressed in various tissues, including the brain and the heart. NUP88 has been shown to interact with cofilin and to play a role in the regulation of actin dynamics, which is important for the maintenance of cell stability and the regulation of cell division.

In addition to its role in the regulation of the cell cycle and the actin cytoskeleton, NUP88 has also been shown to contribute to the development of cancer through its role in the regulation of cellular processes that are important for the development and progression of cancer. For example, NUP88 has been shown to play a role in the regulation of the angiogenesis, which is the process by which new blood vessels are formed in the body. In cancer cells, angiogenesis is often disrupted, leading to the loss of blood supply and the failure of tumor growth.

Overall, NUP88 is a protein that has been shown to play a role in the regulation of various cellular processes that are important for the development and progression of cancer. Its potential as a drug target makes it an attractive target for the treatment of various diseases, including cancer. As further research continues to identify the various mechanisms by which NUP88 contributes to the development and progression of cancer, the potential for NUP88 as a drug target becomes increasingly clear.

Protein Name: Nucleoporin 88

Functions: Component of nuclear pore complex

The "NUP88 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about NUP88 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets